CSC
TVTX icon

Caldwell Sutter Capital’s Travere Therapeutics TVTX Stock Holding History

Caldwell Sutter Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Buy
+693
New +$30.7K 0.01% 434

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caldwell Sutter Capital's TVTX Position: Q2 2026 in Review

Caldwell Sutter Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 693 shares worth $39.4K. The stake represents 0.01% of the portfolio and ranks #434 among its holdings.

321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Caldwell Sutter Capital held 693 shares of Travere Therapeutics worth $39.4K as of Q2 2026.
  • Travere Therapeutics was a new Caldwell Sutter Capital position in Q2 2026.
  • Travere Therapeutics made up 0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #434 holding.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.